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Background: Diabetic patients commonly present an increased risk for cardiovascular events, for which aspirin
is the most frequently used medication for primary prevention. Urinary 11-dehydro thromboxane (11-
dhTXB2) concentrations assess the effect of aspirin on platelets and identify patients who are at risk of
cardiovascular events. The present study investigated whether or not type 2 diabetic patients who took a daily
dose of 100 mg of aspirin had a signiﬁcant reduction in urinary 11-dhTXB2 concentrations and whether these
results were associated with clinical and laboratory variables.
Methods: Eighty-one type 2 diabetic patients were enrolled in the study. Laboratory tests included the
determination of lipidic proﬁle, glycated hemoglobin, platelets count, molecular analysis for both GPIIbIIIa
and COX-1 polymorphisms, and urinary 11-dhTXB2.
Results: Patients' median value for urinary 11-dhTXB2 before aspirin intake was 179 pg/mg of creatinine. After
15 days taking aspirin, the patients presented median of 51 pg/mg of creatinine, thus revealing a signiﬁcant
difference between medians (p=0.00). A reduction of 95% in urinary 11-dhTXB2 concentrations could only
be identiﬁed in 4 patients (5%). A BMI of ≥26 presented a signiﬁcant association with a reduction of urinary
11-dhTXB2 concentrations (p=0.010), as shown by the multiple logistic regression model. Other clinical and
laboratory variables showed no association.
Conclusions: Regardless of the mechanisms related to aspirin non-responsiveness, most patients enrolled in
the present study also presented a reduced or minimal response to low-dose aspirin therapy, thereby
indicating a clear variability related to aspirin effectiveness. Moreover, BMI appears to be independently
associated to the reduction of urinary 11-dhTXB2 concentrations in type 2 diabetic patients taking aspirin.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Type 2 diabetic patients commonly present an increased risk for
cardiovascular events. Aspirin therapy was jointly recommended in
2007 by the American Diabetes Association (ADA) and the American
Heart Association (AHA) for the primary prevention in type 2 diabetes
mellitus patients with increased cardiovascular risk [1]. Given that it
inhibits thromboxane A2 (TXA2) synthesis, aspirin is the most
frequently used antithrombotic medication and reduces the risk of
cardiovascular events by N25% in a broad category of patients [2,3]. Ite Federal University of Minas
orizonte, Minas Gerais, 31270-
. Carvalho).
vier OA license.exerts its major antithrombotic effect by irreversibly acetylating
platelet cyclooxygenase-1 (COX-1), thereby blocking the formation of
TXA2. Urinary concentrations of 11-dehydro thromboxane (11-
dhTXB2), a stable metabolite of TXA2, can indicate the extent of
inhibition of TXA2 generation as well as platelets activation [4–6].
High concentrations of urinary 11-dhTXB2 when undergoing aspirin
therapy indicate an incomplete inhibition of TXA2 synthesis and has
been associated with an increased risk of cardiovascular events [7].
Recent studies suggest that some patients do not beneﬁt from
aspirin's effect on TXA2 synthesis as a means of primary prevention,
especially in diabetic patients. The meta-analysis study of the
Antithrombotic Trialist Collaboration found that low aspirin doses
for the primary prevention of serious vascular events did not beneﬁt
patients in the same manner that it did for secondary prevention [6].
In another meta-analysis study [8], it was reported that aspirin
1367L.H. Gonçalves et al. / Clinica Chimica Acta 412 (2011) 1366–1370therapy in diabetic patients for primary prevention does not
signiﬁcantly reduce the risk of cardiovascular events. Data from
clinical trials have shown that the aspirin effect may vary in an
individual manner, and that obesity and poor glycemic control may
inﬂuence platelet reactivity [9,10] and are associated with a poor
response to aspirin antiplatelet effects [11,12].
Aspirin responsiveness has also been associated with genetic
polymorphisms of the platelet glycoprotein (GP) IIbIIIa gene, a Leu
(PlA1) to Pro (PlA2) substitution at position 33 of the GP IIIa subunit
[13–15] and of cyclooxygenase-1 gene, a two single-nucleotide poly-
morphisms, A-842G and C50T, which are in complete linkage disequi-
librium [16–18].
According to Patrono et al. [19], acetylation of the COX-1 platelet
does not attain functional relevance until the maximal capacity to
generate thromboxane A2 is reduced by at least 95%. This reduction
can be assessed by urinary 11-dhTXB2 measurements. Therefore, this
study aimed to measure the urinary 11-dhTXB2 concentrations of
type 2 diabetic patients before and during aspirin intake to verify
whether or not a 95% reduction had in fact been achieved.
Considering that urinary 11-dhTXB2 concentrations have been used
to assess the effect of aspirin on platelets and identify patients who are
at risk of cardiovascular events, the aim of this study was to investigate
the aspirin responsiveness in type 2 diabetes patients bymeasuring the
urinary 11-dhTXB2 concentrations and by determining whether or not
these results can be affected by clinical and molecular variables. As
aspirin still continues to be prescribed to millions of individuals
worldwide as a useful tool for the prevention of thrombotic events, it
was deemed pertinent to investigate how asymptomatic type 2 diabetic
patients from our geographic region respond to the administration of
aspirin in low doses, considering that prior literature reveals a wide
range of variability in the effectiveness of aspirin [20–22].
2. Materials and methods
A single center study was conducted on a cohort of type 2 diabetic
patients attending the outpatient clinic of the Santa Casa Hospital in
Belo Horizonte, Brazil. A total of 81 type 2 diabetic patients (58
females and 23males) with a mean age of 57.20±9.85 years (ranging
from 30 to 81 years) and who were taking 100 mg of aspirin daily
(distributed for free by the Brazilian Public Health Service), were
enrolled in the study. Laboratory and statistical analyses were
performed at the Faculty of Pharmacy from the Federal University of
Minas Gerais (UFMG), Brazil. The study was conducted between June
2008 and June 2010. Local institutional ethics committees approved
this study and informed consent was obtained from all participants.
Patients were selected sequentially following inclusion and
exclusion criteria and type 2 diabetes diagnosis was deﬁned according
to the criteria of American Diabetes Association [23]. Only patients
who declared no use of aspirin for at least two weeks prior to blood
collection and with a medical prescription for a daily intake of 100 mg
of aspirin were included. Exclusion criteria were therapy with other
antiplatelet agents, unfractionated or low molecular weight heparin,
antithrombotic and nonsteroidal anti-inﬂammatory drugs, chronic or
acute inﬂammatory diseases, hepatic or renal disease, surgery at any
time during the last six months and pregnancy. Descriptive data as
well as body weight and height were obtained during patient
interviews and from health records taken on the day of the invitation.
2.1. Laboratory investigation
Blood laboratory tests included the determination of total and HDL
cholesterol, triglycerides, glycated hemoglobin (HbA1c), platelets
count, and molecular analysis of GPIIbIIIa (PIA) and COX-1 poly-
morphisms. Urine analysis included creatinine and 11-dhTXB2.
Blood samples were obtained by clean venipuncture after 12 h of
overnight fasting on the day before beggining treatment with aspirinand on the ﬁfteenth day after taking 100 mg of daily. A sample was
drawn in one test tube with no anticoagulant to obtain serum on both
days. Another sample was drawn in a second tube with EDTA
(Sarsted®) to obtain platelet count, glycated hemoglobin (HbA1c)
and a molecular analysis on the ﬁrst blood collection day only. All
participants were asked to provide a ﬁrst morning urine specimen on
both days of blood collection. Serum and urine samples were divided
into aliquots and stored at −80 °C until analysis. Platelets count and
HbA1c dosage were performed on the same day of blood collection.
Genomic DNA was extracted from peripheral white blood cells on the
following day using “Wizard Genomic DNA Puriﬁcation” (Promega
Inc., Madison, WI), according to standard protocols.
Stored urine and serum samples were thawed at the moment of
analysis. Urinary 11-dhTXB2 was quantitatively measured using a
commercially available enzyme immunoassay (Cayman Chemical Co,
Ann Arbor MI 11-dhTXB2 EIA kit) with interassay and intra-assay
coefﬁcients of variation of 12.2% and 10%, respectively. Urinary
creatinine was measured using colorimetric method.
Total and HDL cholesterol as well as triglycerides were analysed by
enzimatic colorimetric method. LDL cholesterol was calculated using
Friedwald's equation. HbA1c was measured using ion exchange
chromatography method. Platelets count was obtained using Coulter
T-890®.
GPIIbIIIa (PIA) gene polymorphism was studied using a polymer-
ase chain reaction–restriction fragment length polymorphism (PCR-
RFLP) technique [14,24]. The C50T COX-1 polymorphism (with C50T
in complete linkage disequilibrium with A-842G) was detected using
a nested polymerase chain reaction–restriction fragment length
polymorphism technique [25]. All assays were performed by
laboratory staff blinded to sample identiﬁcation. Compliance to
treatment was self-reported.
2.2. Statistical analysis
All data were checked for normality using the Shapiro Wilk test.
Results were represented as mean and standard deviation (SD) when
data were normally distributed. When abnormally distributed, data
were presented as median and interquartile range. Statistical analysis
was initially performed usingPearson Chi-square, Mann Whitney,
KruskalWallis, t test andWilcoxon tests andwas considered signiﬁcant
when pb0.05. To examine the association between baseline patients
characteristics and the reduction of urinary 11-dhTXB2 concentrations,
variables signiﬁcant to 0.20 concentrationwere selected by a univariate
analysis to be submited to a multiple logistic regression model.
Goodness of ﬁt for this model was assessed using the Hosmer and
Lemeshow test. A pb0.05 was considered statistically signiﬁcant in the
ﬁnal multiple logistic regression. All analyses were performed using the
Statistical Package of the Social Sciences software (SPSS), ver 13.0.
3. Results
Sixty eight patients presented a diagnosis of hypertension, 9 of
whom were current smokers while 18 were prior smokers. Six
patients had no prior history of medication to control diabetes. Oral
hypoglycemic medication was used by 66 patients, while 50 used
insulin. Statin therapy was used by 45 patients. Patients presented a
median body mass index (BMI) of 30 kg/m2 (interquartile range: 25–
32 kg/m2), a mean platelets count of 235±57/mm3 and a median
HbA1c of 8.0% (interquartile range: 6.7–8.8%). The lipidic proﬁle of
patients showed a median total cholesterol of 189 mg/dl (interquar-
tile range: 160–214 mg/dl), HDL cholesterol of 49 mg/dl (interquar-
tile range: 42–58 mg/dl), LDL cholesterol of 107 mg/dl (interquartile
range: 90–131 mg/dl) and triglycerides of 130 mg/dl (interquartile
range: 93–178 mg/dl).
Patients' median value for urinary 11-dhTXB2 immediately before
aspirin intake was 179 pg/mg creatinine (interquartile range: 117–
Table 1
Urinary 11-dhTXB2 levels before and after 15 days of aspirin intake, according to participants' characteristics.
Participants' characteristics Median (IQR) 11-dh TXB2 before
aspirin intake (pg/mg creatinine)
Median (IQR) 11-dh TXB2 after
aspirin intake (pg/mg creatinine)
p value* % reduction
Male (n=23) 151 (215–104) 52 (70–33) 0.00 66
Female (n=58) 204 (320–131) 51 (80–32) 0.00 75
p value** 0.107 0.814
Hypertensive (n=68) 179 (284–117) 52 (81–33.5) 0.00 71
Nonhypertensive (n=13) 179 (315–61) 46 (77–23) 0.015 74
p value** 0.852 0.563
Current smoker (n=9) 268 (477–215) 68 (161–34) 0.021 75
Prior smoker (n=18) 179 (277–97.5) 64 (88–43) 0.001 64
Non smoker (n=54) 164 (284–117) 45 (72–32) 0.00 72
p value*** 0.165 0.201
BMI≤25 kg/m2 (n=18) 163 (211–82) 63 (99–32) 0.005 61
BMI N25≤30 kg/m2 (n=21) 174 (335–101) 51 (70–34) 0.00 71
BMIN30 kg/m2 (n=42) 208 (326–147.5) 48 (79–30) 0.00 77
p value*** 0.173 0.591
Total cholesterol≤200 mg/dL(n=52) 176 (290–111) 51 (70–31) 0.00 71
Total cholesterolN200 mg/dL (n=29) 179 (296–149) 54.00 (89–36) 0.00 70
p value** 0.708 0.183
LDL cholesterol≤130 mg/dL(n=60) 188 (306–116) 51 (72–31) 0.00 73
LDL cholesterol N130 mg/dL(n=21) 160 (253–139) 54 (99–36) 0.00 66
p value** NS NS
Triglycerides≤150 mg/dL (n=49) 174 (284–117) 46 (74–31) 0.00 74
Triglycerides N150 mg/dL (n=32) 179 (371–118) 52 (88–40) 0.00 71
p value** NS NS
HbA1c≤7.0% (n=24) 174 (239–119) 51 (66–23) 0.00 71
HbA1cN7 b10% (n=40) 165 (298–117) 50 (81–36) 0.00 69
HbA1c≥10.0% (n=17) 219 (361–103) 65 (90–32) 0.025 70
p value*** NS NS
GP IIbIIIa polymorphism absent (n=60) 179 (326–120) 55 (88–33) 0.00 69
GP IIbIIIa polymorphism present (n=21) 156 (216–116) 36 (57–30) 0.00 77
p value** NS 0.034
COX-1 polymorphism absent (n=65) 179 (284–124) 46 (85–31) 0.000 74
COX-1 polymorphism present (n=16) 180 (316–100) 53 (72–48) 0.001 71
p value** NS NS
IQR = interquartile range; BMI = body mass index; * Wilcoxon test; **Mann Whitney test; ***Kruskal Wallis test.
Table 2
Multiple logistic regression model using a reduction of 50–100% in urinary 11-dhTXB2
levels as a response variable.
Variable Reduction
≥50–100%
Reduction
b50–100%
OR CI 95% OR p value
N(%) N(%)
BMI (kg/m2)
≤25 10 (50.0) 10 (50.0) 1
N25≤30 21 (84.0) 4 (16.0) 6.939 [1.592;30.243] 0.010
N30 30 (83.3) 6 (16.7) 5.510 [1.531;19.836] 0.009
BMI = body mass index; OR = Odds ratio; CI = Conﬁdence Interval; Goodness-of-ﬁt
logistic regression by Hosmer and Lemeshow test (p=0.338).
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a median urinary 11-dhTXB2 of 51 pg/mg creatinine (interquartile
range: 32–79 pg/mg creatinine). Thus, a signiﬁcant difference between
medians could be observed (p=0.00; Wilcoxon test).
GPIIbIIIa (PIA) polymorphism studies showed that the allele PIA1A2
was present in 19 patients (heterozygosity) while the allele PIA2A2
was found in 2 patients (homozygosity). Among the 81 patients
studied, 10 were heterozygous for the C50T polymorphism and 6
were homozygous .
The expected reduction of 95% in urinary 11-dhTXB2 concentra-
tions after aspirin intake [26] could only be identiﬁed in 4 patients
(5%) while a reduction of 90% was found in 10 patients (12%).
Reductions in urinary 11-dhTXB2 concentrations of 76–100% could be
observed in 36 patients, of 51–75% in 24 patients and of 26–50% in 9
patients. Three patients presented a reduction of 1–25%. One patient
presented no change in urinary 11-dhTXB2 concentrations and
8 presented higher concentrations after 15 days taking 100 mg of
aspirin most likely due to an inﬂammatory state during this period.
Table 1 shows a comparison focusing on the percentage of
reduction in urinary 11-dhTXB2 concentrations according to patients'
characteristics. From all variables analysed only GPIIb/IIIa polymor-
phism (PIA1A2+PIA2A2), as compared to those with wild type (PIA1A1),
appears to show a favorable effect on the urinary 11-dhTXB2
concentrations, in turn leading to a signiﬁcant reduction in the
concentrations of this marker (p=0.034).
Considering a reduction of over 90% in urinary 11-dhTXB2 concen-
trations as an independent variable, no studied variable could be included
in the multiple logistic regression model, given that no variable reached
the limit of p≤0.20 in an univariate analysis. This ismost likely due to the
fact that this reduction could only be identiﬁed in 14 patients (17%).
Considering a reduction of 50–100% in urinary 11-dhTXB2 concentrationsas an independent variable, only BMI and oral hypoglycemic use reached
the limit of p≤0.20. Hence, these variables could be included in the
multiple logistic regression. According to this model a reduction of≥50–
100% in urinary 11-dhTXB2 concentrations proved to be signiﬁcantly
associated with BMI only as shown by the multiple logistic regression
model (Table 2). Thus, patients with a BMI of N25 kg/m2 and ≤30 kg/m2
present a nearly 7 times greater chance of lower concentrations of urinary
11-dhTXB2, (OR=6.939; CI=1.592–30.243; p=0,010), i.e., a higher
percentage of reduction in the concentrations of thismarker, as compared
to patients with BMI≤25 kg/m2, while patients with a BMI of N30 kg/m2
tend to present a nearly 5.5 times greater chance (OR=5.510;
CI=1.531–19.836; p=0.009).
4. Discussion
It is widely recognised that regional and demographic character-
istics may affect clinical and lab variables in different manners. As
physicians must be aware of the variability of aspirin effectiveness in
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or not aspirin is working properly in type 2 diabetes patients, in this
case, those selected from a Brazilian population sample.
Although the expected 95% of reduction in urinary 11-dhTXB2
concentrations was not achieved, median values of 11-dhTXB2 before
and after aspirin intake were statistically different (p=0.00). Zisman
et al. [27] studied healthy individuals and aspirin-treated patients and
found that urine concentrations of 11-dhTXB2 were approximately
three times lower with aspirin treatment than without, although in
two patients concentrations were higher with aspirin. Our results
show that median urinary 11-dhTXB2 concentrations were more than
three times lower after aspirin intake in most patients. Carrol et al.
[28] assayed 11-dhTXB2 concentrations in the ﬁrst voided urine
samples collected 2–8 h after interventional cardiology procedures
performed on aspirin resistant and aspirin sensitive patients. Values
were signiﬁcantly higher (p=0.008) in the aspirin resistant group
(845±614 pg/mg creatinine, n=14) as compared to the aspirin
inhibited group (493±348 pg/mg creatinine, n=46). These values
are much higher than those of the present study, as they reﬂect the
inﬂammatory state triggered by interventional cardiology procedures.
Our study population presented basic characteristics which can be
found in the realm of patients who attend specialized public health
care clinics in Brazil in an attempt to control diabetes. Women tended
to be the predominant patients. In addition, only 11% reported being
current smokers, most likely because the patients had become
conscious of the risks that tobacco brings to diabetic patients. Almost
all patients presented reasonable total and LDL cholesterol concen-
trations probably because those who presented hypercholesterolemia
were taking statin. However, patients' HbA1c concentrations proved
to be undesirable, given that the mean value found was 8% whereas
the limit value that indicates a good glycemic control is 7%. Median
body mass index found for the group (30 kg/m2) also indicated a poor
weight control and nearly obese patients. Analysing these data as a
whole may partly explain why patients with usual doses of aspirin
showed an incomplete suppression of urinary 11-dhTXB2 suggesting
an increased risk of subsequent vascular events.
Undas et al. [29] studied GPIIbIIIa (PIA) polymorphism and found
that the allele PIA2 is expressed in platelets of approximately 25% of all
caucasians, while Pamukcu et al. [14] found 22% with the PIA1A2 allele
but no one with the PIA2A2 in a population of 94 patients. The present
study found that the GPIIbIIIa (PIA) polymorphism was not correlated
to a reduction in urinary 11-dhTXB2 concentrations. Pamukcu et al. [14]
found no statistically signiﬁcant relation between aspirin resistance and
GPIIbIIIa (PIA) polymorphism while Macchi et al. [13] concluded that
homozygous platelets (PIA2A2 allele) appeared to be less sensitive to
inhibitory action of aspirin administered in low doses. Surprisingly, in
the present study, lower concentrations of urinary 11-dhTXB2 in
patients presenting the GPIIbIIIa (PIA) polymorphism (PIA1A2 and
PIA2A2), as compared to those with the wild type (p=0.034; Table 1),
could be observed. However, the small number of patients assayed as a
whole and consequently the very small subset of patients presenting
the PIA2 allele (2 homozygous and 19 heterozygous) preclude any
conclusive comment on its association with 11-dhTXB2 concentrations
in patients taking aspirin.
At the present study, among the 81 patients studied, 12.35% were
heterozygous for the C50T polymorphism and 7.40% were homozy-
gous. However, COX-1 polymorphism did not affect the reduction in
urinary 11-dhTXB2 concentrations, which is in agreement with the
results found by Pettinella et al. [30].
Eikelboom et al. [7] found that increasing age, female sex, current
smoking, and oral hypoglycemic or angiotensin-converting enzyme
inhibitor therapy were independently associated with higher con-
centrations of 11-dhTXB2 in patient urine, whereas statin treatment
was associatedwith lower concentrations. The present study found no
association between these variables and a reduction in urinary 11-
dhTXB2 concentrations. By contrast, it was observed that only thebody mass index presented a signiﬁcant association with the
reduction in urinary 11-dhTXB2 concentrations. This result suggests
that aspirin resistance is negatively associatedwith obesity in patients
with type 2 diabetes, given that the reduction of urinary 11-dhTXB2
concentrations was higher in patients with BMI N25 kg/m2. The
association of BMI and reduction of the aspirin effect on urinary 11-
dhTXB2 concentrations were comparable in subjects with BMI of N25
and≤30 kg/m2 and subjects with BMI of N30 kg/m2 (Table 2). A small
size of the subject population may explain the unexpected results
related to a higher odds ratio for BMI N25 and≤30 kg/m2 compared to
the odds ratio for BMIN30 kg/m2 and this ﬁnding constitutes a
limitation of this study.
Opposite ﬁndings have recently been reported in studies by Cohen
et al. and Ertugrul et al., using platelet aggregation as a method for
evaluating COX-1 inhibition by aspirin. On the other hand, a recent
study by Frelinger et al. showed that serum thromboxane B2
concentrations proved to be higher in aspirin-treated patients with
obesity than in those without obesity. Comparing our results with
those found by these investigators, from the viewpoints of method-
ology, the discrepancies may be explained by different doses of drug,
the type of assay used, patient population and studied size sample,
among other factors, such as, statin and antidiabetic drugs used in
parallel, the duration of the diabetes, glycemic control, etc. The
measurement of urinary 11-dhTXB2 concentrations is more direct and
sensitive for evaluating COX-1 activity than is platelet aggregation.
Thus, our assay evaluated the generation of urinary 11-dhTXB2, which
depends on in vivo platelet activation, whichmay be a reﬂection of the
total atherothrombotic burden, among other factors. It is known that
urinary 11-dhTXB2 may be derived, in part, from nonplatelet sources.
Therefore, it can be concluded that, in the Brazilian aspirin-treated
patient population, the variable response to this drug was due in part
to incomplete COX-1 inhibition as well as to COX-1-independent
platelet hyperreactivity. Whether aspirin response in patients with
diabetes type 2 is associated to BMI warrants further investigation
involving a larger number of individuals in an attempt to clarify these
conﬂicting ﬁndings.
Emerging evidence of variable response to the administration of
aspirin in low doses was conﬁrmed in the present study in a small set
of Brazilian asymptomatic type 2 diabetes patients who showed
biochemical evidence of persistent thromboxane-dependent platelet
activation supported by high concentrations of 11-dhTXB2 in their
urine samples. Potential mechanisms involved may include acceler-
ated platelet turnover, drug bioavailability, competitive interference
by other NSAID's, platelet polymorphisms, hyperlipidemia, diet and
lifestyle, reduced COX-1 binding capacity by aspirin due to COX-1
hyperglication and enhanced thromboxane production by COX-2,
among others.
Despite the small number of investigated cases, our results from
the local area of Belo Horizonte, Brazil, conﬁrm previous reports
developed in other regions of the world which focus on an insufﬁcient
suppression of thromboxane generation with low-dose aspirin intake.
Considering that as much as a 95% redution in the urinary 11-dhTXB2
concentrations is essential to prevent cardiovascular events [19],
clinical cointerventions to minimize the effect of modiﬁable variables
may well represent an effective strategy for the management of
patients showing a limited antiagregant response to low-dose aspirin
intake.
Therefore, the lack of aspirin responsiveness should be the basis
for other alternatives measures such as other antiplatelet therapies
and clinical cointerventions in addition to diet and lifestyle changes,
in order to reduce the risk of cardiovascular events.
Finally, another important aspect to be considered is that urinary
11-dhTXB2 is not subjected to the preanalytical variables associated
with other blood-based indirect measures of platelet activation.
Urinary 11-dhTXB2 constitutes a readily available marker for in vivo
platelet activation and its quantiﬁcation may be very useful for
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ering that an ineffective response may lead to an increased risk of
death. Thus, the correct identiﬁcation of patients who are not
adequately protected despite their usual prescribed daily dose of
aspirin is warranted. In addition, facilities for running 11-dhTXB2
assays may encourage lab professionals to introduce this procedure
into the clinical routine.
5. Conclusion
Regardless of the mechanisms related to aspirin non-responsive-
ness, most patients enrolled in the present study also presented a
reduced or minimal response to low-dose aspirin therapy, thereby
indicating a clear variability related to aspirin effectiveness. Within
the present study's conditions, gender, age, hypertension, smoking
habits, insulin use, oral hypoglycemic use, statin intake, as well as
platelet count, total and HDL cholesterol, triglycerides and HbA1c
concentrations, and GPIIbIIIa and COX-1 polymorphisms did not affect
urinary 11-dhTXB2 concentrations. However, higher body mass index
appeared to be independently associated with the reduction in
urinary 11-dhTXB2 concentrations in Brazilian asymptomatic type 2
diabetic patients taking aspirin.
List of abreviations11-dhTXB2 11-dehydro thromboxane B2
COX-1 Cyclooxygenase-1
GP Platelet glycoprotein
TXA2 Thromboxane A2
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